# A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F

Source: https://onco.cc/trials/nct07730489/  
OnCo record `nct07730489` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of trastuzumab brengitecan, regorafenib, fruquintinib and trifluridine/tipiracil in colorectal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan is a phase 3, randomised interventional study registered as NCT07730489 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 130 participants, started 2026-08 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M07D1; Regorafenib; Fruquintinib; TAS-102. Conditions listed: Colorectal Cancer. Primary outcome: BICR-assessed Progression-free Survival (PFS). Colorectal eligibility wording from the registry: "Patients with histologically or cytologically confirmed metastatic colorectal cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07730489
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT07730489: https://clinicaltrials.gov/study/NCT07730489

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07730489.json